Skip to main content
Authored Items
First-Line Nivolumab Combination Therapy Improves Survival in Patients with Advanced Esophageal Squamous-Cell Carcinoma: CheckMate-648
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 in From the Literature, Gastrointestinal Cancers, Checkpoint Inhibitors
Second-Line Axicabtagene Ciloleucel Therapy Improves Outcomes in Patients with Large B-Cell Lymphoma: ZUMA-7
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 in From the Literature, Lymphoma, CAR T-Cell Therapy
Pembrolizumab plus Chemotherapy for Neoadjuvant and Adjuvant Therapy in Early Triple-Negative Breast Cancer: KEYNOTE-522
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2022 Vol 12, No 2 in From the Literature, Breast Cancer, Checkpoint Inhibitors
Low-Dose Capecitabine Maintenance Therapy Improves Survival in Patients with Triple-Negative Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 in From the Literature, Breast Cancer, Dose Escalation/Reduction
Enfortumab Vedotin Superior to Chemotherapy in Urothelial Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 in From the Literature, Bladder Cancer
Oral Azacitidine Prolongs Survival in Patients with Acute Myeloid Leukemia
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2021 Vol 11, No 2 in From the Literature, Leukemia
Adding Tucatinib to Trastuzumab and Capecitabine Improves Survival in HER2-Positive Metastatic Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2020 Vol 10, No 2 in From the Literature, Breast Cancer
Trastuzumab Deruxtecan Shows Durable Antitumor Activity in HER2-Positive Metastatic Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2020 Vol 10, No 2 in From the Literature, Breast Cancer
First-Line Osimertinib Therapy Boosts Overall Survival in Non–Small-Cell Lung Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - April 2020 Vol 10, No 2 in From the Literature, Lung Cancer
Novel Systemic Therapies for Advanced Non–Small-Cell Lung Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA, Tristan Lindfelt, PharmD, BCPS, BCACP, BCOP, Eric Lozano
JHOP - March 2017 Vol 7, No 1
Concise Review of Obinutuzumab in the Treatment of Patients with Chronic Lymphocytic Leukemia
Peter Tang, PharmD Candidate, Tristan Lindfelt, PharmD, BCPS, BCACP, BCOP, Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2014 VOL 4, NO 2 in Drug Profiles/Updates
Rituximab Maintenance Prolongs Progression-Free Survival in Patients with Relapsed Follicular Lymphoma Undergoing High-Dose Chemotherapy and Autologous Transplantation
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2013 VOL 3, NO 2 in From the Literature
Crizotinib Superior to Standard Chemotherapy in Patients with ALK-Positive Lung Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2013 VOL 3, NO 2 in From the Literature
Neoadjuvant Lapatinib and Trastuzumab with Hormonal Therapy and No Chemotherapy Beneficial in Patients with HER2 Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2013 VOL 3, NO 2 in From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2013 VOL 3, NO 1
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - December 2012 VOL 2, NO 4 in From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2012, Vol 2, No 2 in From the Literature
Bevacizumab Delays Progression in Women with Advanced Ovarian Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2012, VOL 2 NO 1 in From the Literature, From the Literature
Combination Therapy with Pertuzumab Offers New Option in Metastatic Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2012, VOL 2 NO 1 in From the Literature, From the Literature
Chemotherapy-Induced Changes in Brain Structure Correlate with Cognitive Dysfunction
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2012, VOL 2 NO 1 in From the Literature, From the Literature
BRAF Inhibitor Therapy Linked to Squamous-Cell Carcinoma in Patients with RAS Mutations
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2012, VOL 2 NO 1 in From the Literature, From the Literature
Adding Bevacizumab to Neoadjuvant Chemotherapy Improves Complete Response Rates in Patients with Breast Cancer
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2012, VOL 2 NO 1 in From the Literature, From the Literature
Concise Reviews from the Literature Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - September 2011, Vol 1, No 3 in From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - June 2011, Vol 1, No 2 in From the Literature
Concise Reviews of Studies Relevant to Hematology Oncology Pharmacy
Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA
JHOP - March 2011, Vol 1, No 1
Last modified: May 2, 2022